Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NNC0487-0111 vs Low Energy Diet or Placebo on Energy Metabolism in Overweight/Obesity
NCT07757087Phase 1Recruiting
- Sponsor
- Novo Nordisk
- Start
- Aug 2026
- Primary completion
- Sep 2028
- Countries
- 2
01
Overview
Phase 1, randomised trial of amycretin in obesity and Overweight (3 arms), sponsored by Novo Nordisk. Primary endpoint: Sleeping Metabolic Rate. Started Aug 2026; status: recruiting.
02
Drugs
amycretin
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on NCT07757087.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07757087.